The global, regional, and national burden of psoriasis in 195 countries and territories, 1990-2017: A systematic analysis from the Global Burden of Disease Study 2017.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Few existing studies on the global incidence, prevalence, and burden of disease from psoriasis are of high quality, making reliable data and comparisons difficult to find.We analyzed global psoriasis trends […]

» Read more

Real life efficacy and safety of secukinumab in elderly psoriasis patients over a 2-year period.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Psoriasis prevalence is increasing among elderly subjects. Elderly psoriasis patients represent a challenge for dermatologists due to multiple comorbidities, polypharmacy, immune senescence which lead to increased possibility of adverse events, […]

» Read more

Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

There is a lack of any overview of changes over time and variation in the epidemiology of psoriasis with age and between genders.To perform a systematic review of published population-based […]

» Read more

The risk of interstitial lung disease during biological treatment in Japanese patients with psoriasis.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

As biological agents have been widely used for the treatment of psoriasis, increasing numbers of interstitial lung disease (ILD) associated with biologics are reported. Many were associated with tumor necrosis […]

» Read more

Global burden of psoriasis – comparison of regional and global epidemiology, 1990 to 2017.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Psoriasis is a common disease that has not only cutaneous manifestations but also causes significant systemic illness and disability. Most epidemiological studies on the burden of psoriasis that are available […]

» Read more

Treatment of erythrodermic psoriasis with biologics: A systematic review.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Biologic medications for plaque psoriasis have been used to treat erythrodermic psoriasis (EP). Since the guidelines for management of EP were published, new biologics have been approved for the treatment […]

» Read more

The risk of myocardial infarction, stroke and revascularization among patients with psoriasis treated with apremilast compared to biologics and DMARDs: a cohort study in the United States MarketScan database.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Click here to read the full article @ Journal of the American Academy of Dermatology

» Read more

Long term safety of nine systemic medications for psoriasis: a cohort study using the Biobadaderm Registry.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Registry studies broadly describing the safety of systemic drugs in psoriasis are needed.To describe the safety findings of systemic drugs (acitretin, adalimumab, apremilast, cyclosporine, etanercept, infliximab, methotrexate, secukinumab, ustekinumab) used […]

» Read more

Risk of Hospitalisation and Death due to Infection in People with Psoriasis: a Population-based Cohort Study using the Clinical Practice Research Datalink.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Psoriasis is associated with risk factors for serious infections, but the independent relationship between psoriasis and serious infection is as yet unclear.To determine whether people with psoriasis have a higher […]

» Read more

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 – a rapid update.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

The overall aim of the guideline is to provide up-to-date, evidence-based recommendations on the use of biologic therapies targeting TNF (adalimumab, etanercept, certolizumab pegol, infliximab), IL12/23p40 (ustekinumab), IL17A (ixekizumab, secukinumab), […]

» Read more

Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in pediatric patients (≥6 to <12 years of age): efficacy, safety, pharmacokinetic, and biomarker results from the open-label CADMUS Jr study.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Limited options are available for treatment of pediatric psoriasis.To evaluate the efficacy and safety of ustekinumab in pediatric psoriasis patients (≥6 to <12 years of age).CADMUS Junior (Jr), a phase […]

» Read more

Sex- and gender-associated clinical and psychosocial characteristics of patients with psoriasis.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Sex and gender may affect disease prevalence, adverse effects and response to therapy.To analyse sex- and gender differences in psoriasis outpatients.A cross-sectional study was conducted at IDI-IRCCS, Rome, over a […]

» Read more

Is psoriasis associated with dementia or cognitive impairment? A Critically Appraised Topic.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Is psoriasis associated with dementia or cognitive impairment?.Psoriasis is a multisystemic inflammatory disorder that has an unclear association with cognitive dysfunction. This Critically Appraised Topic synthesizes the results from relevant […]

» Read more

Serious infection risk in children with psoriasis on systemic treatment: a propensity score matched population-based study.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Psoriasis (PsO) is increasingly treated with systemic medications, yet their safety is not well characterized in children.We sought to estimate the 6-month risk of serious infections in children with PsO […]

» Read more

Joint Aad-Npf Guidelines Of Care For The Management Of Psoriasis With Systemic Non-Biological Therapies.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 2% of the world’s population. In this guideline, we focus the discussion on systemic, non-biologic medications for […]

» Read more

Drug Survival of Adalimumab, Ustekinumab, and Secukinumab in Patients with Psoriasis: a Prospective Cohort Study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Real-world biologic drug survival is an important proxy measure for effectiveness. Predictors of drug survival may help patients with psoriasis choose between biologic therapies.1. To assess the relative drug survival […]

» Read more

Acute onset of psoriasis in a patient with atopic dermatitis treated with dupilumab.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Atopic dermatitis (AD) is a chronic, multifactorial, inflammatory skin disease which can have a negative impact on the quality of life (QoL). The moderate-to-severe forms frequently require systemic treatment. Dupilumab […]

» Read more

What are the barriers to physical activity in patients with chronic plaque psoriasis?

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Psoriasis is associated with an increased risk of cardiovascular disease (CVD). Despite recommendation that exercise is important for cardiorespiratory fitness, patients with psoriasis avoid participation in physical activities for reasons […]

» Read more
1 2 3 6